Cargando…

2644. Evaluation of Clinical Course and Heath-Related Quality-of-Life Following Treatment with Oseltamivir, Laninamivir, and Baloxavir Marboxil in Adult Patients with Seasonal Influenza: Prospective Observational Study

BACKGROUND: Influenza is currently being treated in Japan with 4 types of neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir marboxil. Among these, baloxavir marboxil is the newest agent and currently available in limited countries, while the clinical efficacy of this dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshino, Yusuke, Misu, Keita, Wakabayashi, Yoshitaka, Ota, Yasuo, Kitazawa, Takatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809710/ http://dx.doi.org/10.1093/ofid/ofz360.2322

Ejemplares similares

Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study
por: Yoshino, Yusuke, et al.
Publicado: (2020)

922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
por: Hansen, Svenn, et al.
Publicado: (2023)

Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020)

Exposure to low temperatures suppresses the production of B-cell activating factor via TLR3 in BEAS-2B cells
por: Yoshino, Yusuke, et al.
Publicado: (2020)

1518. Real-World Comparative Effectiveness of Baloxavir Marboxil versus Oseltamivir on Influenza-Related Complication and Resource Utilization
por: Neuberger, Eddie, et al.
Publicado: (2020)

Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir
por: Nezu, Keiko, et al.
Publicado: (2023)

Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)

2255. Fibroblast Growth Factor 23, a Potential Risk Factor for Cardiovascular Diseases Is Associated with Abacavir/Lamivudine Use in HIV Patients
por: Yoshino, Yusuke, et al.
Publicado: (2018)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil
por: Yoshino, Ryunosuke, et al.
Publicado: (2019)

The Clinical Effect of Seasonal Flu Vaccination on Health-Related Quality of Life
por: Yoshino, Yusuke, et al.
Publicado: (2021)

729. Comparing Length of Stay and Clinical Outcomes for Hospitalized Patients at Bridgeport Hospital who Received Baloxavir Marboxil (BM) or Oseltamivir Phosphate (OP) During the 2018–2019 Influenza Season
por: Nachiappan, Arun C, et al.
Publicado: (2019)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018)

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020)

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals
por: Liu, Yanmei, et al.
Publicado: (2022)

1350. Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2018)

Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims Database( )
por: Miyazawa, Shogo, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications
por: Koshimichi, Hiroki, et al.
Publicado: (2020)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
por: Kiso, Maki, et al.
Publicado: (2019)

Hyaluronic Acid Concentration in Pleural Fluid: Diagnostic Aid for Tuberculous Pleurisy
por: Yoshino, Yusuke, et al.
Publicado: (2015)

Inhibition of osteoblast differentiation by ritonavir
por: Wakabayashi, Yoshitaka, et al.
Publicado: (2018)

2256. Baloxavir Marboxil in Combination with Oseltamivir in Two Critically Ill Patients with Influenza A (H1N1; 2009 strain) on Veno-Venous Extra-Corporal Membranous Oxygenation
por: Ntem-Mensah, Afua Duker, et al.
Publicado: (2019)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
por: Taniguchi, Keiichi, et al.
Publicado: (2022)

The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor
por: Todd, Brendan, et al.
Publicado: (2021)

Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
por: Kim, Yun, et al.
Publicado: (2021)

Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis
por: Seldeslachts, Laura, et al.
Publicado: (2021)

Baloxavir marboxil: un potente inhibidor de la endonucleasa cap-dependiente de los virus gripales
por: Reina, Jordi, et al.
Publicado: (2019)

LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
por: Ison, Michael G, et al.
Publicado: (2018)

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
por: Lou, Yan, et al.
Publicado: (2021)

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019)

Relationship of sleep disorders with long-term complications and health-related quality of life in people with well-controlled human immunodeficiency virus
por: Yoshino, Yusuke, et al.
Publicado: (2022)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings
por: Koshimichi, Hiroki, et al.
Publicado: (2018)

2645. Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A
por: Shah, Sunish, et al.
Publicado: (2019)

Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
por: Nakauchi, Mina, et al.
Publicado: (2020)

Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002
por: Hamza, Hazem, et al.
Publicado: (2021)

Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study
por: Komeda, Takuji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c34h5spfluoe6hrllka6guh1uq